

Probiotics and the gastrointestinal tract: Where are we in 2005?

Irit Chermesh, Rami Eliakim

Irit Chermesh, Rami Eliakim, Gastroenterology Department, Rambam Medical Center, Haifa, Israel

Correspondence to: Professor Rami Eliakim, Gastroenterology Department, Rambam Medical Center, P.O.B 9602, Haifa 31096, Israel. r_eliakim@rambam.health.gov.il

Telephone: 972-4-8541912 (Mobile: 972-50-2062323)

Fax: 972-4-8543058

Received: 2005-08-15

Accepted: 2005-09-12

Abstract

Probiotic agents are live microbes or components of microbes that have a positive effect on the host. They exert their action through interplay with the immune system of the host. Some of this effect is local and some is systemic. The full story is yet to be discovered. Probiotics have a definite positive effect on rotavirus diarrhea, post antibiotic diarrhea and pouchitis. Their exact role in inflammatory bowel disease, irritable bowel syndrome, other forms of infectious diarrhea, and prevention of cancer is yet to be determined. This review summarizes the data about probiotics in these conditions.

© 2006 The WJG Press. All rights reserved.

Keywords: Probiotics; Inflammatory bowel disease; Crohn's disease; Lactose intolerance; Antibiotic associated diarrhea; Rotavirus; Pseudomembranous colitis; Clostridium difficile; Irritable bowel syndrome; Toll like receptor 9

Chermesh I, Eliakim R. Probiotics and the gastrointestinal tract: Where are we in 2005? *World J Gastroenterol* 2006; 12(6): 853-857

<http://www.wjgnet.com/1007-9327/12/853.asp>

INTRODUCTION

The modern term 'probiotic' was first used by Fuller^[1], describing a live microbial feed supplement which beneficially affects the host animal by improving its microbial balance. Later it was demonstrated that heat-inactivated bacteria or fragments of bacterial DNA have positive effects as well. Marteau *et al*^[2] in 2002 defined probiotics as 'microbial cell preparations or components of microbial cells that have a beneficial effect on the health and well-

being'. The mechanisms by which probiotics beneficially affect the host are multiple. Probiotics can prevent or ameliorate diarrhea and inflammation through their local effects and/or their effect on the immune system. In the gut, probiotic bacteria are thought to occupy binding sites on the gut mucosa, preventing pathogenic bacteria from adhering to the mucosa^[3,4]. Lactobacilli produce proteinaceous compounds, namely bacteriocins, that act as local antibiotics against more pathogenic organisms^[5,6] and decrease production of pro-inflammatory cytokines such as IFN- γ , TNF- α and IL-12^[7-9]. Probiotics stimulate IgA production^[10]. Lactobacilli produce acetic and lactic acid and inhibit the growth of bacterial pathogens^[3]. It has been postulated that probiotics compete with pathogens for nutrients and modify toxins produced by pathogens or toxin receptors found in the gut wall. Rachmilewitz *et al*^[11] have shown that specific DNA repeats isolated from probiotics (VSL #3) can attenuate experimental colitis in various animal models. This is true even with inactivated bacteria. By using toll-like receptor 9 (TLR-9) deficient mice, they have proved that TLR9 signaling is essential in mediating the anti-inflammatory effect of probiotics^[12].

Prerequisites for probiotics are to be effective and safe. The characteristics of an effective probiotic as defined by Saavedra^[11] are resistance to digestion by enteric or pancreatic enzymes, gastric acid and bile, ability to prevent the adherence, establishment and/or replication of pathogens in the gastrointestinal tract.

Examples of probiotic bacteria are members of the Lactobacilli family such as *Lactobacillus rhamnosus* GG, bifidobacteria and the yeast *saccharomyces boulardii*. There are many candidate bacteria which can be qualified as probiotics, but different bacteria have different actions in different disease states, taking into account that some disease states are better treated with a combination of bacteria and that there is an issue of dosing and viable vs. non viable components of the bacteria. Treatment with probiotics is relatively safe, but not risk free. Probiotics are potentially pathogenic^[13]. A recent report describes 3 patients with fungemia in whom the probiotic origin was proven by DNA fingerprinting^[14]. Reports of infections of probiotic origin emphasize the fact that these patients are usually immunosuppressed with multiple ports of entry, such as venous and urinary catheter.

This article reviews the use of various probiotics in the treatment of infectious diarrhea, inflammatory bowel disease and lactose intolerance.

PROBIOTICS AND DIARRHEAL DISEASE

Probiotics have been proved to be beneficial to four types of diarrhea: rotavirus diarrhea, antibiotic-associated diarrhea, clostridium difficile diarrhea, and traveler's diarrhea.

Trials of probiotics for other infectious diarrhea diseases have not been consistent in terms of efficacy so far. Paton *et al*^[15] have produced toxin binding probiotics in a breakthrough study using a toxin-binding recombinant probiotic for the treatment and prevention of enterotoxigenic *Escherichia coli* diarrhea. If these probiotics can be proved effective, it might open a whole new era in the treatment of different kinds of diarrhea.

ACUTE VIRAL DIARRHEA

One of the established benefits of probiotics is that they are effective in the treatment of children with acute viral enteritis^[16,17]. *Lactobacillus reuteri* can shorten the course of acute diarrhea in infants from 2.5 days to 1.5 days^[18]. *Lactobacillus casei* GG is effective in treating acute diarrhea as well^[19]. Different strains of probiotics exhibit different efficacy. Kaila *et al*^[20] studied different lactic acid bacteria for their effect on the immune response to rotavirus in children with acute rotavirus gastroenteritis and found that *Lactobacillus casei* subsp. *casei* strain GG (LGG) is most effective on disease duration and produces the highest titers of IgA antibodies. It has been postulated that IgA specific Ab confers immunity against future infectious diarrhea, a higher level of such Ab is desired. Allan *et al*^[21] systematically reviewed 23 papers concerning probiotic treatment of infectious diarrhea and concluded that probiotics appear to be a useful adjunct to rehydration therapy in treating acute infectious diarrhea in adults and children.

ANTIBIOTIC-ASSOCIATED DIARRHEA AND PSEUDOMEMBRANOUS COLITIS

Antibiotic-associated diarrhea (AAD) is seen in up to 39% of hospitalized patients treated with antibiotics^[22] and varies from uncomplicated diarrhea to colitis and pseudomembranous colitis. The pathogenic factors include any one or all the followings: use of antibiotics causing changes in the normal gut flora, pathogenic bacteria taking advantage of the situation and causing inflammation and diarrhea, change in bacterial flora causing changes in carbohydrate metabolism and changes in short chain fatty acid metabolism and absorption. The latter is interfered and osmotic diarrhea ensues. The well-known syndrome of pseudomembranous colitis characterized by high levels of toxin forming *Clostridium difficile* may take a fulminate course with a high recurrence and mortality rate. AAD can be prevented or treated with probiotics. A meta-analysis summing the results of nine controlled trials indicates that both *Lactobacilli* and *S. boulardii* are effective in preventing AAD^[23]. Various probiotics have been used to prevent and treat *Clostridium difficile*-associated pseudomembranous colitis, including *S. boulardii*, *Lactobacillus* GG, *B. longum* and *B. longum* with *L. acidophilus*. *S. boulardii* and fecal

transplantation can be used through a naso-enteric tube or as an enema^[24]. *S. boulardii* seems to be a choice in prevention and treatment of recurrent *Clostridium difficile* pseudomembranous colitis^[24].

INFLAMMATORY BOWEL DISEASE

Inflammatory bowel disease (IBD) has a complex etiology. Environmental as well as genetic factors play a role. It has been established that microbes play a crucial role in IBD though search for an infectious agent has been futile so far. It was reported that *Lactobacillus* and bifidobacteria counts are significantly reduced in feces of patients with Crohn's disease compared to those with ulcerative colitis and controls and continuous interplay exists between the immune system and intestinal flora, suggesting that normalization of gut flora is a logical means of treatment^[25,26]. Venturi *et al*^[25] treated 20 ulcerative colitis patients with VSL#3 and it is able to change the gut microflora because the faecal concentrations of *Streptococcus salivarius* ssp. *thermophilus*, *Lactobacilli* and bifidobacteria were significantly increased in all patients, compared to their basal level which remained stable throughout study. As mentioned before, probiotics have local and systemic effects. *Lactobacillus casei* strain GG given to pediatric Crohn's patients results in increased serum titers of IgA^[27]. It was also reported that murine colitis was successfully treated with *Lactococcus lactis* secreting interleukin-10^[28].

Probiotics can achieve and maintain remission, prevent post surgical recurrence of Crohn's disease and pouchitis, and treat pouchitis, but an established role of probiotics exists only in the latter two indications. Gosselink *et al*^[29] treated 39 patients with *L. rhamnosus* GG and proved that it had a better effect on these patients than on those not treated with it. Gionchetti *et al*^[30,32] demonstrated that pouchitis episode was reduced by 30% using VSL#3 in a double blind placebo-controlled study. Mirura *et al*^[31] and Kuisma *et al*^[33] showed that remission of chronic pouchitis can be achieved with antibiotics. *S. boulardii* has no efficacy on ulcerative colitis^[34].

Treatment of active ulcerative colitis has been extensively investigated in clinical trials^[34-37]. All the studies proved that probiotics are effective at least on one of the followings: clinical and endoscopic improvement or decrease in proinflammatory cytokine expression. One additional report described six active refractory patients treated with human probiotic infusions and symptoms were abolished in all within four months^[38]. These data support using probiotics in mild to moderate active disease. Three trials showed probiotics can be used as a maintenance treatment of UC^[39-41].

Clinical trials have also been conducted in Crohn's disease patients^[42-45]. Campieri *et al*^[45] compared mesalazine with VSL#3 in 40 patients and found that endoscopic recurrence was significantly reduced noted in probiotic-treated patients, but *Lactobacillus* GG and *L. Jonhsonii* effect cannot prevent post surgical recurrence of Crohn's disease. Treatment of active Crohn's disease has been assessed in some studies^[46,47], no definite conclusion could be reached due to methodological drawbacks.

LACTOSE MALABSORPTION

Lactase deficiency is a frequent condition causing intolerance to lactose due to maldigestion. Kolars *et al*^[48] and Savaiano *et al*^[49] in 1984 showed that absorption of lactose from yogurt is improved compared with milk, presumably due to digestion of lactose by lactase released from the yogurt microorganisms^[50]. Shermak *et al*^[51] examined the effect of yogurt or milk on symptoms and hydrogen breath concentration in children with lactose intolerance and found that symptoms as well as exhaled hydrogen concentration were lower in children challenged with yogurt.

IRRITABLE BOWEL SYNDROME

Evidence for benefit of probiotic treatment in irritable bowel syndrome (IBS) has not been consistent. Nobaek *et al*^[52] conducted a double-blind, randomized placebo-controlled study in 60 unselected patients with IBS, and found that probiotic treatment resulted in improvement of flatulence only. Recently, O'Mahony *et al*^[53] reported patients taking *B. infantis* had improvement in their symptoms, but no difference was observed between patients treated with *L. salivarius* and those treated with placebo. An interesting finding was that the basal ratio of IL-10/IL-12 was lower in IBS patients than in matched healthy controls. Treatment with *B. infantis* but not *L. salivarius* or placebo led to normalization of the ratio, suggesting that inflammation plays a role in the pathogenesis of IBS.

PROBIOTICS AND CANCER

It is assumed that cancer is the outcome of genetic and environmental conditions. In each individual the interplay between the two is different. Cancer is the endpoint of a series of events. Various studies have shown the effect of probiotics on some of the enzymatic pathways and intermediates assumed to precede cancer^[54-56]. Brady *et al*^[54] have summarized the data concerning the use of probiotics in the prevention of cancer in their review. Other studies reported that the use of probiotics is inversely related with aberrant crypts or tumor development^[55,56]

POTENTIAL BENEFIT OF PROBIOTICS

Treatment of constipation with probiotics has yielded confusing results^[57,58]. Probiotic *E. coli* strain has been found to be effective on collagenous colitis^[59].

CONCLUSION

Probiotics are a large group of microbes. Different microbes have different actions in different situations. Probiotics play a definite role in a number of clinical situations, namely rotavirus diarrhea, post antibiotic diarrhea and pouchitis. Their role in other clinical situations is yet to be defined.

REFERENCES

1 Fuller R. Probiotics in man and animals. *J Appl Bacteriol* 1989;

- 66: 365-378
- 2 Marteau P, Cuillerier E, Meance S, Gerhardt MF, Myara A, Bouvier M, Bouley C, Tondou F, Bommelaer G, Grimaud JC. *Bifidobacterium animalis* strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. *Aliment Pharmacol Ther* 2002; **16**: 587-593
- 3 Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive *Escherichia coli* (EIEC). *Gut* 2003; **52**: 988-997
- 4 Servin AL, Coconnier MH. Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens. *Best Pract Res Clin Gastroenterol* 2003; **17**: 741-754
- 5 Dembele T, Obdrzalek V, Votava M. Inhibition of bacterial pathogens by lactobacilli. *Zentralbl Bakteriol* 1998; **288**: 395-401
- 6 Ocana VS, Elena Nader-Macias M. Production of antimicrobial substances by lactic acid bacteria II: screening bacteriocin-producing strains with probiotic purposes and characterization of a *Lactobacillus bacteriocin*. *Methods Mol Biol* 2004; **268**: 347-353
- 7 Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. *J Biol Chem* 2002; **277**: 50959-50965
- 8 Di Caro S, Tao H, Grillo A, Elia C, Gasbarrini G, Sepulveda AR, Gasbarrini A. Effects of *Lactobacillus GG* on genes expression pattern in small bowel mucosa. *Dig Liver Dis* 2005; **37**: 320-329
- 9 Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action. *Curr Opin Gastroenterol* 2005; **21**: 426-430
- 10 Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human *Lactobacillus* strain. *Pediatr Res* 1992; **32**: 141-144
- 11 Saavedra JM. Microbes to fight microbes: a not so novel approach to controlling diarrheal disease. *J Pediatr Gastroenterol Nutr* 1995; **21**: 125-129
- 12 Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. *Gastroenterology* 2004; **126**: 520-528
- 13 Ishibashi N, Yamazaki S. Probiotics and safety. *Am J Clin Nutr* 2001; **73**: 465S-470S
- 14 Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, Rincon C, Hortal J, Pelaez T. *Saccharomyces cerevisiae* fungemia: an emerging infectious disease. *Clin Infect Dis* 2005; **40**: 1625-1634
- 15 Paton AW, Jennings MP, Morona R, Wang H, Focareta A, Roddam LF, Paton JC. Recombinant probiotics for treatment and prevention of enterotoxigenic *Escherichia coli* diarrhea. *Gastroenterology* 2005; **128**: 1219-1228
- 16 Pearce JL, Hamilton JR. Controlled trial of orally administered lactobacilli in acute infantile diarrhea. *J Pediatr* 1974; **84**: 261-262
- 17 Pene P, Linhard J, Bernou JC. [The colibacillus-lactobacillus combination in the treatment of diarrhea in adults, children and infants] *Sem Hop* 1966; **42**: 241-244
- 18 Shornikova AV, Casas IA, Mykkanen H, Salo E, Vesikari T. Bacteriotherapy with *Lactobacillus reuteri* in rotavirus gastroenteritis. *Pediatr Infect Dis J* 1997; **16**: 1103-1107
- 19 Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human *Lactobacillus* strain (*Lactobacillus casei* sp strain GG) promotes recovery from acute diarrhea in children. *Pediatrics* 1991; **88**: 90-97
- 20 Kaila M, Isolauri E, Saxelin M, Arvilommi H, Vesikari T. Viable versus inactivated lactobacillus strain GG in acute rotavirus diarrhoea. *Arch Dis Child* 1995; **72**: 51-53
- 21 Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. *Cochrane Database Syst Rev* 2004; **2**: CD003048
- 22 McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. *Dig Dis* 1998; **16**: 292-307
- 23 D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis.

- BMJ* 2002; **324**: 1361
- 24 **Surawicz CM**. Probiotics, antibiotic-associated diarrhoea and *Clostridium difficile* diarrhoea in humans. *Best Pract Res Clin Gastroenterol* 2003; **17**: 775-783
- 25 **Venturi A**, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. *Aliment Pharmacol Ther* 1999; **13**: 1103-1108
- 26 **Laake KO**, Bjornekleit A, Aamodt G, Aabakken L, Jacobsen M, Bakka A, Vatn MH. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configured ileal-pouch-anal-anastomosis in ulcerative colitis. *Scand J Gastroenterol* 2005; **40**: 43-51
- 27 **Malin M**, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with *Lactobacillus GG*. *Ann Nutr Metab* 1996; **40**: 137-145
- 28 **Steidler L**, Hans W, Schotte L, Neiryck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by *Lactococcus lactis* secreting interleukin-10. *Science* 2000; **289**: 1352-1355
- 29 **Gosselink MP**, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain *Lactobacillus rhamnosus GG*. *Dis Colon Rectum* 2004; **47**: 876-884
- 30 **Gionchetti P**, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. *Gastroenterology* 2003; **124**: 1202-1209
- 31 **Mimura T**, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. *Gut* 2004; **53**: 108-114
- 32 **Gionchetti P**, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. *Gastroenterology* 2000; **119**: 305-309
- 33 **Kuisma J**, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of *Lactobacillus rhamnosus GG* on ileal pouch inflammation and microbial flora. *Aliment Pharmacol Ther* 2003; **17**: 509-515
- 34 **Guslandi M**, Giollo P, Testoni PA. A pilot trial of *Saccharomyces boulardii* in ulcerative colitis. *Eur J Gastroenterol Hepatol* 2003; **15**: 697-698
- 35 **Furrie E**, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'neil DA, Macfarlane GT. Synbiotic therapy (*Bifidobacterium longum*/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. *Gut* 2005; **54**: 242-249
- 36 **Kato K**, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A, Arakawa Y. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. *Aliment Pharmacol Ther* 2004; **20**: 1133-1141
- 37 **Tursi A**, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. *Med Sci Monit* 2004; **10**: P1126-P1131
- 38 **Borody TJ**, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. *J Clin Gastroenterol* 2003; **37**: 42-47
- 39 **Kruis W**, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic *Escherichia coli* Nissle 1917 is as effective as with standard mesalazine. *Gut* 2004; **53**: 1617-1623
- 40 **Rembacken BJ**, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic *Escherichia coli* versus mesalazine for the treatment of ulcerative colitis: a randomised trial. *Lancet* 1999; **354**: 635-639
- 41 **Ishikawa H**, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. *J Am Coll Nutr* 2003; **22**: 56-63
- 42 **Prantera C**, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with *Lactobacillus GG*. *Gut* 2002; **51**: 405-409
- 43 **Van Gossium A**, Geboes KD, De Vos MB, Louis E, Enslen M, Paintin M, Franchimont D. A randomized Placebo-Controlled Trial of Probiotics (*L. Jonhsonii*, Lal) on Early Endoscopic Recurrence of Crohn's Disease After Ileo- Caecal Resection. Abstract DDW 2005 #: 98
- 44 **Philippe MR**, Marc L, Philippe S, David L, Jean Frederic, Yoram B, Guillaume C, Jean Claude S, Arnaud B, Etienne M, Eric L, Franck C, Jean Louis D, Michel V, Jean Yves M. Ineffectiveness of the Probiotic Strain *Lactobacillus Johnsonii* Lal in Preventing Recurrence After Curative Resection for Crohn's Disease- a Randomized Double- Blind Placebo Controlled Trial. Abstract DDW2005 # 97
- 45 **Campieri M**, Rizzello F, Venturi A et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomised controlled study vs mesalazine. *Gastroenterology* 2000; **118**: A781.
- 46 **Malchow HA**. Crohn's disease and *Escherichia coli*. A new approach in therapy to maintain remission of colonic Crohn's disease? *J Clin Gastroenterol* 1997; **25**: 653-658
- 47 **Gupta A**, Andrew H, Kirschner BS, Guandalini S. Is *Lactobacillus GG* helpful in children with Crohn's disease? Results of a preliminary, open-label study. *J Pediatr Gastroenterol Nutr* 2000; **31**: 453-457
- 48 **Kolars JC**, Levitt MD, Aouji M, Savaiano DA. Yogurt--an autodigesting source of lactose. *N Engl J Med* 1984; **310**: 1-3
- 49 **Savaiano DA**, AbouElAnouar A, Smith DE, Levitt MD. Lactose malabsorption from yogurt, pasteurized yogurt, sweet acidophilus milk, and cultured milk in lactase-deficient individuals. *Am J Clin Nutr* 1984; **40**: 1219-1223
- 50 **Saavedra JM**. Clinical applications of probiotic agents. *Am J Clin Nutr* 2001; **73**: 1147S-1151S
- 51 **Shermak MA**, Saavedra JM, Jackson TL, Huang SS, Bayless TM, Perman JA. Effect of yogurt on symptoms and kinetics of hydrogen production in lactose-malabsorbing children. *Am J Clin Nutr* 1995; **62**: 1003-1006
- 52 **Nobaek S**, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. *Am J Gastroenterol* 2000; **95**: 1231-1238
- 53 **O'Mahony L**, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. *Lactobacillus* and *bifidobacterium* in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. *Gastroenterology* 2005; **128**: 541-551
- 54 **Brady LJ**, Gallaher DD, Busta FF. The role of probiotic cultures in the prevention of colon cancer. *J Nutr* 2000; **130**: 410S-414S
- 55 **Marotta F**, Naito Y, Minelli E, Tajiri H, Bertuccelli J, Wu CC, Min CH, Hotten P, Fesce E. Chemopreventive effect of a probiotic preparation on the development of preneoplastic and neoplastic colonic lesions: an experimental study. *Hepatogastroenterology* 2003; **50**: 1914-1918
- 56 **Yamazaki K**, Tsunoda A, Sibusawa M, Tsunoda Y, Kusano M, Fukuchi K, Yamanaka M, Kushima M, Nomoto K, Morotomi M. The effect of an oral administration of *Lactobacillus casei* strain shirota on azoxymethane-induced colonic aberrant crypt foci and colon cancer in the rat. *Oncol Rep* 2000; **7**: 977-982
- 57 **Koebnick C**, Wagner I, Leitzmann P, Stern U, Zunft HJ. Probiotic beverage containing *Lactobacillus casei* Shirota improves gastrointestinal symptoms in patients with chronic constipation. *Can J Gastroenterol* 2003; **17**: 655-659

- 58 **Banaszkiewicz A**, Szajewska H. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. *J Pediatr* 2005; **146**: 364-369
- 59 **Tromm A**, Niewerth U, Khoury M, Baestlein E, Wilhelms G, Schulze J, Stolte M. The probiotic E. coli strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial. *Z Gastroenterol* 2004; **42**: 365-369

S- Editor Wang XL and Guo SY **L- Editor** Elsevier HK **E- Editor** Bai SH